SGLT-2 Inhibitors in Heart Failure: Putting the Evidence Into Practice
Published: 27 August 2021
Following the release at ESC 2021 of updated guidelines for the diagnosis and treatment of acute and chronic heart failure, Prof Andrew Coats (Monash University, Australia and University of Warwick, UK) and Prof Giuseppe Rosano (St George's, University of London, UK) discuss the implications for treatment strategies.
This three-part series provides comprehensive update on some of the most important developments in HFrEF management including addressing key considerations of where SGLT-2 inhibitors fit into the new guidelines for HFrEF, when and how to initiate SGLT-2 inhibitors, and making evidence-based choices in the selection of SGLT-2 inhibitor.
- Recall the latest recommendations and levels of evidence supporting the use of SGLT-2 inhibitors in heart failure (HF)
- Consider the impact of delaying the adoption of all guideline-directed foundational therapies in existing HF
- Make an evidence-based choice when selecting an SGLT-2 inhibitor in HF
- Heart failure specialists
- Referring physicians
- Allied health professionals
Where Do SGLT-2 Inhibitors Fit Into the New Guidelines for HFrEF?
When and How to Initiate SGLT-2 Inhibitors in HFrEF
Choosing an SGLT-2 Inhibitor – Making an Evidence-based Choice
Andrew JS Coats
Director of the Monash Warwick Alliance and Academic Vice-President
Professor Andrew Justin Stewart Coats was born in Melbourne, Australia on 1 February 1958. His father was a Professor of Resuscitation who first described essential fatty acids.
He is an Australian-British academic cardiologist as well as a successful fundraiser, university administrator and inventor.
Professor Coats attended Melbourne Grammar School and studied at Oxford and Cambridge.9 He has higher doctorates from Oxford (DM) and Imperial (DSc.) and an MBA from London Business School.1
He obtained a Bachelor of Arts in 1979, a Bachelor of Medicine and Surgery in 1981, a Master of Arts in 1982, a PhD in Management in 1989, became a Doctor of Sciences in 1999 and completed a further Masters in Business Administration in 2001.
Consultant Cardiologist and Professor of Cardiology (Hon)
Giuseppe Rosano is Consultant Cardiologist and Professor of Cardiology at St George’s, University of London where he is also the director of MSc Heart Failure.
After obtaining his MD in Medicine and Surgery at the La Sapienza University of Rome, Prof Rosano obtained his specialisation in cardiology from the same University before attaining his PhD in Medical Sciences from Imperial College London. His research interests focus on experimental and clinical pharmacology, heart failure, cardiac metabolism, diabetes and gender differences in cardiovascular diseases.